Loading
Life sciences · Journal article
Russian Journal of Preventive Medicine · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Indole-3-propionate (IPA) is a microbiota-dependent metabolite of tryptophan that is attracting attention as a potential component for modulating the tumor microenvironment and enhancing antitumor therapy. Objective. To analyze current data on the biosynthesis of IPA by the gut microbiota and its influence on cellular processes associated with carcinogenesis, including apoptosis, proliferation, and inflammation. Materials and methods. A literature search was carried out in the Google Scholar and PubMed databases without time restrictions, using keywords in Russian and English: «indole-3-propionate», «cancer», «oncology», «IPA». Results. Based on the performed analysis, we structured the review into several subsections to provide a comprehensive assessment of the effect of IPA on tumor cells. Particular attention is paid to the molecular mechanisms of IPA action, such as activation of antioxidant pathways and regulation of AhR, PI3K/Akt, and NF-κB signaling cascades. The study presents the results of preclinical research using cancer models of various nosologies, identifies the potential for IPA application as a component of combination therapy, and outlines key directions for future research. Conclusion. It has been shown that IPA is a promising bacterial metabolite for developing new strategies for antitumor therapy. Key areas for further research include optimizing IPA delivery regimens, investigating its efficacy in combination with existing treatment methods, and performing clinical trials.